Magna Concursos

Foram encontradas 20 questões.

4257816 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
A teacher uses the article to discuss how pharmaceutical research, regulation, investment and public communication interact across national borders. The teacher wants to avoid turning the lesson into either commercial promotion or an unsupported debate about medical treatment. Register T for true statements and F for false statements.
(   ) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
(   ) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
(   ) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
(   ) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
 

Provas

Questão presente nas seguintes provas
4257815 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
Read the excerpt:
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
 

Provas

Questão presente nas seguintes provas
4257814 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
A teacher prepares an audio adaptation of the article and asks students to identify the difference between confirmed information and market projections. Before listening, the teacher provides the categories confirmed transaction, clinical expectation, and financial estimate. Which procedure most effectively develops the intended listening skill?
 

Provas

Questão presente nas seguintes provas
4257813 Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal 

July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley (ATAI.O) for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health conditions.

The deal taps into rising interest in psychedelics following easing regulations under the Trump administration and reinforces Lilly's push to use windfall weight-loss drug profits to diversify its product portfolio.

Lilly will gain access to AtaiBeckley's lead candidate BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression, a severe form of the illness that does not improve after standard treatments.

Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials. AtaiBeckley expects initial results from the trials in early 2029.

Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% to the stock's closing price on Wednesday. AtaiBeckley's shares rose more than 30% in morning trading.

The offer consists of $2.8 billion upfront and up to $1 billion in milestone-based payments. The companies expect the deal to close in the third quarter.

"The acquisition aligns with Eli Lilly's expanding neuroscience portfolio and offers upside potential in large markets like depression," said Barclays analyst Emily Field.

Shares of psychedelic drug developers Enveric Biosciences (ENVB.O) and GH Research (GHRS.O) were up 6% and 11%, respectively. 

The psychedelics industry could reach $12 billion in revenue by 2034, rivaling the size of branded antidepressants currently at about $8 billion, said RBC Capital Markets analyst Trung Huynh. 

SURGING INTEREST IN PSYCHEDELIC-BASED THERAPIES

Drugmakers have shown growing interest in psychedelic-based treatments for depression and other mental health disorders.

President Donald Trump's executive order in April directed U.S. health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field. 

AbbVie (ABBV.N) last year bought an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.

New York-based AtaiBeckley was formed through a merger between Germany-based Atai Life Sciences and privately held Beckley Psytech in 2025. Billionaire venture capitalist Peter Thiel was an early backer of Atai.

Current medicines for treatment-resistant depression include Johnson & Johnson's (JNJ.N) ketamine-derived nasal spray Spravato — which requires twice-weekly clinic visits — or other invasive interventions. 

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/ 
After reading the article, students compare the headline, financial projections, quoted analysts and descriptions of clinical development. They then produce a short English-language briefing distinguishing facts, forecasts and corporate interests.
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
 

Provas

Questão presente nas seguintes provas
A trajetória histórica de Itapiranga (SC) está relacionada à ocupação e à organização territorial do Extremo Oeste catarinense, processo que contribuiu para a formação de características próprias do município. Sua localização e a constituição do núcleo colonial que antecedeu sua organização político-administrativa são elementos relevantes para compreender a configuração do território itapiranguense. Considerando os aspectos históricos e geográficos de Itapiranga, analise as afirmativas a seguir.
I.O município situa-se em área de fronteira com a Argentina e possui limite interestadual com o Rio Grande do Sul.
II.A colonização organizada na década de 1920 contou com famílias de descendência alemã vinculadas ao catolicismo.
III.A Sociedade União Popular participou da organização do processo colonizador que deu origem à colônia denominada Porto Novo.
IV.A colônia Porto Novo estava, naquele período, administrativamente vinculada ao município de São Miguel do Oeste.
Está correto o que se afirma em:
 

Provas

Questão presente nas seguintes provas
A Lei Orgânica de Itapiranga estabelece competências municipais relacionadas à promoção de objetivos de interesse coletivo e disciplina formas de atuação do poder público junto a organizações da sociedade. Entre essas competências, encontra-se a possibilidade de destinação de recursos a determinadas entidades privadas, desde que observadas as condições previstas na legislação municipal. Considerando os requisitos estabelecidos pela Lei Orgânica para essa finalidade, em qual situação o Município poderá conceder o auxílio financeiro previsto?
 

Provas

Questão presente nas seguintes provas
O enfrentamento de organizações criminosas recebeu novo tratamento legislativo federal no primeiro semestre de 2026, com uma norma sancionada que criou categorias penais relacionadas à atuação de organizações ultraviolentas, grupos paramilitares e milícias privadas.
O texto considera práticas que, mediante violência ou grave ameaça, afetam a paz pública, a segurança coletiva ou instituições.
Entre as novas tipificações estão os crimes de _______________ e de _______________.
Identifique a alternativa que completa corretamente as lacunas acima.
 

Provas

Questão presente nas seguintes provas
"O fato de podermos compartilhar esse espaço, de estarmos juntos viajando não significa que somos iguais; significa exatamente que somos capazes de atrair uns aos outros pelas nossas diferenças, que deveriam guiar o nosso roteiro de vida." KRENAK, Ailton. Ideias para adiar o fim do mundo. São Paulo: Companhia das Letras, 2019.
Assinale a opção que apresenta análise correta do texto.
 

Provas

Questão presente nas seguintes provas
"Fomos, durante muito tempo, embalados com a história de que somos a humanidade. Enquanto isso, enquanto seu lobo não vem; fomos nos alienando desse organismo de que somos parte, a Terra, e passamos a pensar que ele é uma coisa e nós, outra: a Terra e a humanidade." KRENAK, Ailton. Ideias para adiar o fim do mundo. São Paulo: Companhia das Letras, 2019.
Assinale a opção que apresenta análise correta do texto.
 

Provas

Questão presente nas seguintes provas
"Quando retirei a faca da mala de roupas, embrulhada em um pedaço de tecido antigo e encardido, com nódoas escuras e um nó no meio, tinha pouco mais de sete anos." VIEIRA JUNIOR, Itamar. Torto Arado. São Paulo: Todavia, 2019. (abertura do capítulo 1)
Assinale a opção que apresenta análise correta do texto.
 

Provas

Questão presente nas seguintes provas